

Company name Nectin Therapeutics \* Website <https://www.nectintx.com/> \* CEO name Yaron Daniely \* \* Select a CATEGORY: Biotech/Pharma “Redefining the Fight Against Cancer: New Targets, New Modalities.”

Nectin Therapeutics (NectinTx) is a clinical stage biotechnology company and a trailblazer in oncology drug development, with a focus on addressing unmet needs in cancer treatment. Its lead product, NTX1088, is a first in class immune checkpoint inhibitor directed against PVR (NECL5), a novel target overexpressed in more than 50% of cancers. NTX1088 has demonstrated robust activity across a wide range of indications in patients who have exhausted all available treatment options. NectinTx has developed a diverse pipeline of first and best in class therapies, including antibody–drug conjugates (ADCs) that are showing superiority over approved and clinically explored ADCs. These ADCs are being developed in collaboration with world leading technology partners, including LCB. NectinTx’s dedication to innovation and excellence has earned recognition from prestigious organizations such as the Cancer Focus Fund, MD Anderson Cancer Center, and Merck MSD, which collaborated with the company to advance its phase 1 trial. The company’s pipeline of novel and potent therapies has also attracted investment from leading healthcare investors, including aMoon, Peregrine Ventures, IBF, and GIBF.